Panitumumab (Panitumumabum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antineoplastic agents - monoclonal antibodies

Included in the formulation
  • Vectibix
    concentrate d / infusion 
    Amgen Europe BV     Netherlands
    • АТХ:

    L.01.X.C   Monoclonal antibodies

    L.01.X.C.08   Panitumumab

    Pharmacodynamics:

    It has a cytostatic effect against cells expressing the transmembrane glycoprotein from the family of Type I tyrosine kinase receptors.

    Has a high affinity for the receptors of epithelial growth factor, which is a transmembrane glycoprotein from the family of receptors of thyrokinase I type, stimulating the growth of normal epithelial cells and is expressed on tumor cells.

    It binds to the ligand-binding domain of epithelial growth factor, thereby inhibiting autophosphorylation processes induced by transmembrane glycoproteins from the tyrosine kinase receptor family I type, which leads to inhibition of cell growth, a decrease in the production of vascular endothelial growth factor, interleukin-8, and the induction of apoptosis.

    Pharmacokinetics:

    After intravenous infusion, the elimination half-life is 7.5 days. Elimination by the kidneys.

    Indications:

    Used to treat metastatic colorectal cancer patients who have advanced disease after chemotherapy with oxalaliplatin, iritane, fluoroprimidine.

    ICD-10

    II.C15-C26.C18   Malignant neoplasm of colon

    II.C15-C26.C20   Malignant neoplasm of rectum

    Contraindications:

    Interstitial pneumonitis, individual intolerance.

    Carefully:

    Thrombocytopenia, blood clotting disorders, acute infectious diseases.

    Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
    Dosing and Administration:

    Intravenously Infusion 6 mg / kg once every 2 weeks. for 1 hour, when using a dose of more than 1 g - for 1.5 hours.

    The highest daily dose: 6 mg / kg.

    The highest single dose: 6 mg / kg.

    Side effects:

    Central and peripheral nervous system: headache, dizziness.

    Respiratory system: shortness of breath, cough, embolism of the pulmonary artery, rarely bronchospasm.

    Digestive system: nausea, diarrhea, constipation, abdominal pain, vomiting, stomatitis.

    Dermatological reactions: acne-like dermatitis, exfoliative rash, hirsutism, paronychia, hypertrichosis, alopecia.

    Sense organs: increased tear, conjunctivitis, irritation and hyperemia of the eyes.

    Allergic reactions.

    Overdose:

    Symptoms: diarrhea, dehydration, increased skin reactions.

    Treatment: symptomatic.

    Interaction:

    Contraindicated concurrent use with calcium folinate, irinotecan, fluorouracil, as there is an increase in toxicity.

    Special instructions:

    Monitoring the content of plasma electrolytes.

    If there is and progression of interstitial lung diseases should be canceled application of the drug.

    Instructions
    Up